AI in Medical Devices: Addressing Security and Bias Concerns
We must ensure that cybersecurity and bias concerns are adequately addressed as the role of AI in healthcare and medical devices increases.
The Current Flavour: Life Science in Food and Beverage
Food scientists work to create healthy, flavourful and plant-based products in bid to entice the modern mouths and minds of today’s consumer.
Biotech Talent Recruitment Requires Innovation
Top talent sets a company’s course. They want to know they’ll be empowered scientifically as part of a diverse and positive company culture.
Life Sciences Engineers are the New Rock Stars
Engineers in neuroscience, biotech and telemedicine are at the forefront of our imaginations. Their futures hold challenge and opportunity.
Life Sciences and BioTech Trends Autumn 2020
Real estate developments, investment in artificial intelligence, a gene-editing setback, and success for Vancouver-based biotech companies.
New Tech and New Horizons in Healthcare and Biotech
Life Sciences companies tackle new challenges by embracing new technology and processes in sales, manufacturing, R&D and strategic partnerships.
Technology and the future of biotech and life sciences
The intersection of consumer technology and the biotech and life sciences industries will yield massive returns, if led by the right people.
Collaboration in Life Sciences
New challenges and evolving technologies prompt a spirit of scientific collaboration in the life sciences. Examining the DNA of cooperation.
Biotech Update Spring 2019
Who has the most power in the workplace? Is it your boss? The CEO? Maybe even the board? Historically, maybe, but in one of the tightest biotech labour markets in recent history it’s really the employees that hold the balance of power in the workplace. When someone hands in their notice it generally sets off […]
Biotech: New Year Industry Check-Up
By: Michael Evans, Goldbeck Associate Recruiter – Biotechnology Anyone in the biotech industry is aware of the news dominating the field lately: the Bristol-Myers Squibb (BMS) “mega-deal” acquisition of Celgene valued at $74 billion announced at the start of the year. The deal seems to have left Celgene investors rather pleased with the outcome, with […]